More on EIKN

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (8.3 Score)

Upcoming Events

- Earnings (11/16/26 *Est.)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

(NQ:EIKN)
Delayed: 10.88 +0.42 (4.02%)
Prev. Close $10.46  
Open$10.31 
52 Wk High$ 
52 Wk Low$ 
Day High$10.94 
Day Low$10.10 
P/E N/A  
EPS$ 
Volume333,492 

Friends, Peers and Foes (?): MRK (more...)

Aug 26, 2026 07:30 AM Eikon Therapeutics to Participate in Investor Conferences in September 2026
Aug 21, 2026 08:29 AM Eikon Therapeutics (EIKN) Reiterated at Overweight by Cantor Fitzgerald
Aug 18, 2026 04:15 PM Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald
Aug 14, 2026 06:11 AM Form 8-K Eikon Therapeutics, Inc. For: Aug 13
Aug 13, 2026 05:06 PM Eikon Therapeutics, Inc. (EIKN) Misses Q2 EPS by 163c
Aug 13, 2026 04:13 PM Form 10-Q Eikon Therapeutics, Inc. For: Jun 30
Aug 13, 2026 04:08 PM Form 8-K Eikon Therapeutics, Inc. For: Aug 13
Aug 13, 2026 04:02 PM Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
Aug 11, 2026 07:30 AM Eikon picks dose for phase 2/3 melanoma trial of EIK1001
Aug 11, 2026 07:30 AM Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma
View All Articles

Entities mentioned with EIKN

View All Entities